Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 6.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version
To version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,11 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= **Neurodiagnoses**
6 -//A new tridimensional diagnostic framework for CNS conditions// =
5 += Neurodiagnoses =
7 7  
8 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
9 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
10 10  )))
11 11  )))
12 12  
... ... @@ -14,70 +14,8 @@
14 14  (((
15 15  (% class="col-xs-12 col-sm-8" %)
16 16  (((
17 -= What is this about and what can I find here? =
15 += What can I find here? =
18 18  
19 -==== **Overview** ====
20 -
21 -The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
22 -
23 -* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
24 -* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
25 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
26 -
27 -This methodology enables:
28 -
29 -* Greater precision in diagnosis.
30 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
31 -* Stratification of patients for personalized treatment.
32 -
33 -==== **Diagnostic Axes** ====
34 -
35 -* (((
36 -**Axis 1: Etiology**
37 -
38 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
39 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
40 -* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
41 -)))
42 -* (((
43 -**Axis 2: Molecular Markers**
44 -
45 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
46 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
47 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
48 -)))
49 -* (((
50 -**Axis 3: Neuroanatomoclinical**
51 -
52 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
53 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
54 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
55 -)))
56 -
57 -==== **Case Studies** ====
58 -
59 -1. (((
60 -**Sporadic Alzheimer’s Disease**:
61 -
62 -* Axis 1: Sporadic (ApoE4, poor sleep habits).
63 -* Axis 2: Amyloid-beta plaques, elevated NFL.
64 -* Axis 3: Right hippocampus atrophy (visual memory loss).
65 -)))
66 -1. (((
67 -**Genetic Parkinson’s Disease**:
68 -
69 -* Axis 1: Genetic (LRRK2 mutation).
70 -* Axis 2: Alpha-synuclein aggregation.
71 -* Axis 3: Substantia nigra degeneration (motor dysfunction).
72 -)))
73 -
74 -==== **Applications** ====
75 -
76 -This system enhances:
77 -
78 -* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
79 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
80 -
81 81  == Who has access? ==
82 82  
83 83  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!